Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.
Recently, researchers achieved a crucial discovery that could mitigate and eliminate immune responses causing treatment failure in people with hemophilia A.
Introducing genetic material into the body to treat diseases can work, but making sure that those materials are safely sent to the right location is complicated.
Ghanta, R.K., et al. (2020) Immune-modulatory alginate protects mesenchymal stem cells for sustained delivery of reparative factors to ischemic myocardium. Biomaterials Science. doi.org/10.1039/D0BM00855A.
In a new study from the Wake Forest Institute for Regenerative Medicine (WFIRM) researchers have developed an optimized cellular platform for delivering Factor 8 to better treat patients with hemophilia A.
Transplanted islet cells that release insulin during very low blood sugar levels offer a potential way for treating diabetes.
A team in Massachusetts has established a method of profiling of mispairing in antibody assembly.